Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Given Average Recommendation of “Moderate Buy” by Brokerages

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) has earned a consensus rating of “Moderate Buy” from the six ratings firms that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $55.80.

Several research firms have weighed in on PTHS. Zacks Research upgraded shares of Pelthos Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 24th. Oppenheimer raised their target price on Pelthos Therapeutics from $62.00 to $66.00 and gave the stock an “outperform” rating in a research report on Friday, May 15th. HC Wainwright reiterated a “buy” rating and set a $60.00 price target on shares of Pelthos Therapeutics in a report on Thursday, March 19th. Finally, Cantor Fitzgerald started coverage on Pelthos Therapeutics in a research report on Wednesday, April 1st. They set an “overweight” rating and a $50.00 price target on the stock.

Pelthos Therapeutics Trading Down 3.0%

PTHS stock opened at $27.16 on Friday. Pelthos Therapeutics has a one year low of $16.20 and a one year high of $37.50. The firm’s 50-day moving average price is $26.87. The stock has a market capitalization of $94.52 million, a price-to-earnings ratio of -1.32 and a beta of 3.10. The company has a quick ratio of 1.86, a current ratio of 2.79 and a debt-to-equity ratio of 1.41.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last released its quarterly earnings results on Thursday, May 14th. The company reported ($3.09) earnings per share (EPS) for the quarter. The firm had revenue of $10.91 million for the quarter. On average, equities research analysts anticipate that Pelthos Therapeutics will post -12.63 earnings per share for the current year.

Insiders Place Their Bets

In other Pelthos Therapeutics news, Director Todd C. Davis bought 35,948 shares of the company’s stock in a transaction dated Thursday, June 11th. The shares were bought at an average price of $27.82 per share, for a total transaction of $1,000,073.36. Following the acquisition, the director directly owned 75,834 shares of the company’s stock, valued at approximately $2,109,701.88. This trade represents a 90.13% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Over the last 90 days, insiders sold 1,638 shares of company stock worth $43,107. Insiders own 12.70% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Ikarian Capital LLC increased its stake in Pelthos Therapeutics by 309.5% in the 4th quarter. Ikarian Capital LLC now owns 255,758 shares of the company’s stock valued at $7,928,000 after buying an additional 193,307 shares during the period. Boothbay Fund Management LLC grew its holdings in shares of Pelthos Therapeutics by 279.8% during the 4th quarter. Boothbay Fund Management LLC now owns 80,680 shares of the company’s stock valued at $2,501,000 after acquiring an additional 59,435 shares in the last quarter. J. Goldman & Co LP purchased a new position in shares of Pelthos Therapeutics during the 4th quarter valued at $2,418,000. Cantor Fitzgerald L. P. acquired a new position in shares of Pelthos Therapeutics in the fourth quarter worth $1,085,000. Finally, Diadema Partners LP increased its stake in shares of Pelthos Therapeutics by 138.1% in the fourth quarter. Diadema Partners LP now owns 25,000 shares of the company’s stock worth $775,000 after acquiring an additional 14,502 shares during the last quarter. 77.96% of the stock is owned by hedge funds and other institutional investors.

Pelthos Therapeutics Company Profile

We are a clinical-stage biotech company focused on developing and commercializing new therapeutics to alleviate pain. Our clinical focus is to selectively target the sodium ion-channel known as “NaV1.7”, as well as other receptors in the NaV family. NaV1.7 has been genetically validated as a pain receptor in human physiology. Genetic studies have shown that families with a certain inherited NaV1.7 modulation consistently show a pathology of not feeling pain. A NaV1.7 blocker is a chemical entity that modulates the structure of the sodium-channel in a way to prevent the transmission of pain perception to the central nervous system (“CNS”).